Navigation Links
Dark Ages scourge enlightens modern struggle between man and microbes
Date:12/13/2012

The plague-causing bacteria Yersinia pestis evades detection and establishes a stronghold without setting off the body's early alarms.

New discoveries reported this week help explain how the stealthy agent of Black Death avoids tripping a self-destruct mechanism inside germ-destroying cells.

The authors of the study, appearing in the Dec. 13 issue of Cell Host & Microbe, are Dr. Christopher N. LaRock of the University of Washington Department of Microbiology and Dr. Brad Cookson, UW professor of microbiology and laboratory medicine.

Normally, certain defender cells are programmed to burst if they are either invaded by or detect the presence of pathogens, Cookson explained. This host defense mechanism called pyroptosis ("going up in flames") eliminates places for the germs to reproduce. As it splits open, the cell spills a cauldron of antimicrobial chemicals and emits signals to alert of an attack and its precise location. Tissues become inflamed as more cells arrive to fight the infection.

The bacteria are widely believed to be behind the great pestilences of the Middle Ages in the 1300s. The pathogen had evolved a tactic to delay provoking people's protective inflammatory response until it was too late. Plague claimed an estimated 30 percent to 50 percent of Europe's 14th century population.

"People and pathogens have been in an eternal struggle since the dawn of humanity," Cookson said. With a hand over hand gesture he explained, "Humans continuously ratchet up their defenses, and germs repeatedly find a way around them."

During several medieval epidemics, the plague started in rats. High-jumping fleas transmitted it to and between humans. It commonly caused lymph nodes to rupture. Respiratory forms were more deadly. They damaged the lungs and were spread by sneezing. Plague bacteria in the blood stream ended lives through sepsis, in which the burden of infection overwhelms the body.

Today, the plague-causing bacteria are still circulating in the world. It is held at bay by sanitation measures and drug treatment.

Plague is now rare, with fewer than 15 infections annually in the United States. The number of cases outside the United States is significantly larger, but not precisely known. Plague therefore remains of scientific interest for several reasons.

The Yersinia survival strategy against the programmed death that could kill it and its host cell may offer ideas for vaccine development, Cookson said. At present, no vaccine exists against the plague. Yesinia is of concern as a potential biological warfare pathogen because it can be aerosolized and unsuspectingly breathed into the lungs. Vaccines are being sought to offer widespread public safety, as are methods for enhancing people's overall infection-fighting capacity.

Yersinia's techniques for modulating an inflammatory response also offer scientists an overarching perspective on a fundamental aspect of a variety of important diseases.

"Many medical problems stem from too much or too little inflammatory reaction," Cookson said. People who launch an insufficient inflammatory response, or whose inflammatory response is suppressed by medications, are prone to viral, bacterial and fungal infections.

"On the other hand, excessive or improperly regulated inflammatory responses are responsible for a large number of chronic conditions," Cookson said. These include vascular flare-ups leading to stroke or heart attack, and autoimmune diseases, among them lupus, juvenile diabetes, ulcerative colitis and myasthenia gravis. Severe injury also can promote life-threatening lung inflammation.

Additionally, plague isn't the only pathogen to enhance its virulence by sidestepping the inflammatory cell death program. Several other dangerous germs do the same, but in different ways.

Usually immune system clean-up cells that have been breached by an infection assemble a molecular platform called an inflammasome. This assembly, the researchers explained, activates a powerful, protein-cleaving enzyme called caspase-1. The enzyme is made ready to go in the presence of noxious stimuli, including germs, inorganic irritants, and pore-forming toxins.

To survive, Yersinia pestis must disarm caspase-1. Until the present study, bacterial molecules that directly modulate the inflammasome had not yet been reported. LaRock and Cookson were able to identify a leucine-rich protein secreted by Yersinia pestis that binds and disables its arch-enemy, the caspase-1 enzyme.

The potent substance, called Yop M, preempts the activity of caspase-1 and sequesters the enzyme to arrest the development of the inflammasome. As a consequence, the cell fails to sacrifice itself to get rid of the Yersinia and to warn other disease-fighting cells of the infection.

According to the researchers, the Yop M-mediated inhibition of caspase-1 is required for Yersinia to subvert immune signaling, delay inflammation and provoke severe illness. Its dual mechanism for blocking inflammatory cell death, by blocking enzymatic activity and inflammasome maturation, is distinctive.

While caspase-1 is helpful in combating a number of other microbial infections, several researchers have reported it to be harmful when its activation is aberrant or poorly controlled. Faulty caspase-1 regulation is implicated in several inflammatory disorders. Learning how pathogens manage caspase-1 to their advantage may suggest treatments to limiting its excess activity.


'/>"/>

Contact: Leila Gray
leilag@uw.edu
206-685-0381
University of Washington
Source:Eurekalert  

Related biology news :

1. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
2. Drug could reverse scourge of cerebral malaria for survivors
3. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
4. Ancient whale species sheds new light on its modern relatives
5. Has modern science become dysfunctional?
6. Crime and punishment: The neurobiological roots of modern justice
7. Modern hybrid corn makes better use of nitrogen, study shows
8. Research: Modern Portfolio Theory optimizes conservation practices
9. Squid ink from Jurassic period identical to modern squid ink, U.Va. study shows
10. Woolly mammoth extinction has lessons for modern climate change
11. Fossil egg discovered in Lleida (Spain) links dinosaurs to modern birds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dark Ages scourge enlightens modern struggle between man and microbes
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... April 27, 2017 , ... ... mass flow controllers based on capillary thermal mass flow technology provide exponentially more ... control applications. Over 80% of all industrial processes—such as those involving chemical ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA ... clinical trials comes to Tampa, San Francisco and Boston in 2017. The ... regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the topic will ... place May 15-18, 2017 in Los Angeles, Calif. Hosted by the Workgroup for ...
Breaking Biology Technology: